Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium, Inc. develops novel therapeutics for severe autoimmune and inflammatory disorders. News about EQ centers on EQ504, the company’s investigational aryl hydrocarbon receptor, or AhR, modulator, including preclinical data, clinical-development planning, and disease-area positioning in ulcerative colitis, other gastrointestinal diseases, and inflammatory lung diseases.
Company updates also cover financing activity, operating results, corporate presentations, and equity-award disclosures under Nasdaq inducement-grant rules. These items reflect Equillium’s focus on immunobiology, immunomodulatory assets, capital resources for research and development, and public-company compensation and governance practices.
Equillium (Nasdaq: EQ) reported second quarter 2026 results and corporate updates focused on advancing lead asset EQ504, a selective aryl hydrocarbon receptor modulator. The company plans to submit its Phase 1 dossier in Australia imminently, with a proof‑of‑mechanism SAD/MAD study in healthy volunteers expected to start in Q4 2026 and topline data about six months later.
Equillium is also conducting IND‑enabling work to develop EQ504 as an inhaled therapy for inflammatory lung diseases and EQ302 for celiac disease, and has formed a Clinical Advisory Board for the ulcerative colitis program. Cash and cash equivalents were $57.2 million on June 30, 2026, up from $30.3 million at year‑end 2025, which Equillium believes can fund current plans into 2029. Q2 2026 R&D expenses were $2.8 million and G&A $2.4 million, leading to a net loss of $4.7 million, or $(0.04) per share, compared with a $5.7 million loss a year earlier.
Equillium (Nasdaq: EQ) granted an inducement award of nonstatutory stock options to a new employee under its 2024 Inducement Plan.
The award covers 145,000 shares at an exercise price of $3.08 per share, vesting over four years, and was approved under Nasdaq Listing Rule 5635(c)(4).
Equillium (Nasdaq: EQ) announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55 p.m. EDT. Registered conference investors will also have the opportunity to meet with Equillium’s management team.
Equillium (Nasdaq: EQ) will host a virtual investor webinar on May 27, 2026 at 11:00 AM ET. Chief Scientific Officer Stephen Connelly, Ph.D. will present new preclinical data on Aryl Hydrocarbon Receptor (AhR) modulators and the miR-124 axis in immune and epithelial cells.
The event will share findings that propose a unifying mechanistic framework linking ligand-dependent AhR signaling to miR-124, with implications for inflammatory disease therapy development. A live Q&A and a replay will be available to investors.
Equillium (Nasdaq: EQ) reported first quarter 2026 results and key updates centered on lead candidate EQ504.
The company plans a Phase 1 proof-of-mechanism study for EQ504 in mid-2026 with data about six months later, completed a $35 million private placement, appointed Snehal Naik, Ph.D. as Chief Development Officer, reduced operating expenses and net loss versus 2025, and ended the quarter with $61.3 million in cash, which is expected to fund currently planned operations into 2029.
Equillium (Nasdaq: EQ) announced inducement grants on May 1, 2026 under its 2024 Inducement Plan. The Compensation Committee awarded nonstatutory stock options to purchase an aggregate of 800,000 common shares to two new employees.
Each option’s exercise price equals $2.08 (Equillium’s closing price on May 1, 2026). Options vest over four years: 25% after one year, then monthly over 36 months, subject to continued service and plan/agreement terms, and were approved as an inducement under Nasdaq Listing Rule 5635(c)(4).
Equillium (Nasdaq: EQ) announced that management will present at Oppenheimer’s 2026 Innovation on the Island event on Tuesday, April 28, 2026 at 7:50am AST.
Members of management will be available for investor meetings for registered attendees, providing an opportunity for investor engagement and company updates.
Equillium (Nasdaq: EQ) announced that preclinical data for EQ504 will be presented as posters at IMMUNOLOGY2026™, April 15-19 in Boston. Two posters focus on EQ504 as a potent AhR modulator promoting immune tolerance (IL-10/IL-22) and epithelial barrier repair.
Presentations occur April 16 (Poster 242; speaker 2:30-3:30 PM EDT) and April 18 (Poster 517; speaker 11:30 AM-12:30 PM EDT); posters will be posted on the company Presentations page after each session.
Equillium (Nasdaq: EQ) announced an inducement grant on April 1, 2026: the Compensation Committee awarded a nonstatutory stock option for 32,000 shares to a new employee under the company’s 2024 Inducement Plan.
The option’s exercise price equals $2.04 (closing price on April 1, 2026) and vests over four years: 25% after one year then monthly over 36 months, subject to continued service and plan terms.
Equillium (Nasdaq: EQ) reported fourth-quarter and full-year 2025 results and recent corporate and clinical highlights on March 25, 2026. Key points: no revenue in 2025 versus $41.1M in 2024; FY net loss $22.4M (−$0.39/share); cash and short-term investments $30.3M at Dec 31, 2025; completed a $35M private placement in March 2026 and an up to $50M financing in Aug 2025. Company plans to initiate a Phase 1 proof-of-mechanism study for EQ504 in mid-2026 with data expected ~six months later and expects cash runway into 2029.